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Rheumatoid arthritis is a chronic, systemic inflammatory
disorder that mainly affects joints.  It is the most common form
of inflammatory joint disease, and the second commonest joint
disease, osteoarthritis being the commonest.  The overall
prevalence of rheumatoid arthritis has generally been given as
1% - with females outnumbering males in a ratio of 3-4:1,
although there is some evidence that the incidence of the disease
is decreasing.1 Apart from this, the occurrence of rheumatoid
arthritis is not the same throughout the world.  It is quite rare
in less developed rural parts of the world - thus one study in
Nigeria failed to find one single case.2  Studies in Europe have
shown that there is a gradient in the prevalence of rheumatoid
arthritis, starting from a low prevalence in the South (e.g. Italy
0.31%)3 to a higher prevalence in the North (e.g. Finland 0.8%)4
While no formal epidemiological studies on rheumatoid arthritis
have been carried out in Malta, a total of approximately 600
patients with the disease are followed up at the Rheumatology
Clinic at St. Luke’s Hospital, giving a prevalence of 0.16%.
The first convincing description of rheumatoid arthritis is
found in French medical literature in 1800. 5 However it is
probable that the disease is much older than this.6,7 The term
rheumatoid arthritis was first used in 1859 by Sir Alfred Garrod,
who distinguished the disease from gout.  However, this term
also included polyarticular osteoarthritis and, up until relatively
recently, a number of seronegative arthritides, such as psoriatic
arthritis.  It was Sir Archibald Garrod, Sir Alfred’s son, who
distinguished rheumatoid arthritis from osteoarthritis in 1907.
Aspirin was discovered by Bayer in 1899, and its anti-
inflammatory properties were made use of extensively in the
symptomatic relief of patients with various forms of arthritis,
including rheumatoid arthritis.  The development of
phenylbutazone in 1949 ushered the era of non-steroidal anti-
inflammatory drugs: these remained the mainstay of treatment
of rheumatoid arthritis until the 1970s.
By the late 1800s, which was about the time that rheumatoid
arthritis had been described as a separate disease entity, the
germ theory of disease had already been proven and accepted.
Early studies on rheumatoid arthritis suggested that this disease
might be a response to chronic focal infections; a specific strain
of streptococcus as well as the tubercle bacillus were at various
times considered to play a part in the etiology of the disease.  It
is therefore not surprising that the first attempts to treat the
disease were directed towards removing infected foci from the
body, such as tonsillectomies. Robert Koch’s discovery that gold
compounds could inhibit the growth of tubercle bacilli in vitro
led to the introduction of gold salts in treating rheumatoid
arthritis by Jacques Forestier in 1929.8 Gold was eventually
accepted as standard disease modifying treatment for
rheumatoid arthritis particularly after the results of a major trial
organized by the Empire Research Council were published in
1961.9 In 1949 Forestier attended the 7th International Congress
of Rheumatology in New York where he was to present his
twenty year experience of treating rheumatoid arthritis with
gold: however the key presentation of that meeting was one
dealing with the effects of cortisone in chronic rheumatoid
arthritis delivered by Philip Hench.10  The effects of this
medication were dramatic.  A rapid improvement set in: pains
and tenderness in the joints abated or disappeared and mobility
increased, and for the first time since the onset of their disease
patients who had previously been complete invalids could walk
about freely, and their general condition was also favourably
affected.11  This discovery was considered to be so important
that Hench and his colleagues were awarded the Nobel prize
for Medicine in 1950.  The corticosteroid miracle, however, was
tempered by the serious side effects that started to appear after
prolonged use of these medications, and for several years their
use was not considered to be justified.  Despite this, many
rheumatologists continued to use steroids in some form or other
to treat rheumatoid arthritis, and indeed there is currently
renewed interest in their use.12   An ingenious attempt to
combine an anti-microbial and an anti-inflammatory agent
resulted in the development of sulphasalazine by Dr. N. Svartz
in the 1940s.  However, a trial doubting its efficacy, as well as
the arrival of cortisone, caused its use in rheumatoid arthritis
to decline dramatically, only for it to be re-discovered about 30
years later.13-15 Based on the possibility that rheumatoid arthritis
may initially be triggered by an infection, there have been other
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more recent trials where antibiotics have been used to treat
rheumatoid arthritis.  Thus, in 1999 a small study found that
three to six months of minocycline therapy benefited early-stage
rheumatoid arthritis patients for up to four years after
treatment.16
Peruvian bark, which contains the anti-malarial agent
quinine, was first used in treating fever and rheumatism in the
17th century.  The first time that quinine was used successfully
in the treatment of a rheumatic disease was in the late 1800s,
when Payne, a physician to St. Thomas’ Hospital in London,
described its use in lupus erythematosus.  In a paper by Page in
1951 it was reported that two lupus patients with associated
arthritis had remission of their joint symptoms,17 a finding that
was subsequently confirmed by Bagnall.18  Hydroxychloroquine
was found to be equally effective and less toxic than chloroquine,
and is today the anti-malarial that is most widely used in
rheumatoid arthritis.
Penicillamine, a chelating agent that was first used by
Walshe to treat Wilson’s disease in 1955, was shown to dissociate
macroglobulins such as immune complexes that contain
rheumatoid factor.  Studies in rheumatoid arthritis showed it
to be effective in abut 60% of patients, but a high incidence of
toxicity as well as lack of evidence that it prevents radiological
progression have diminished its use quite considerably.19,20
Methotrexate was introduced as a disease modifying drug
for rheumatoid arthritis in the late 1980s.  This drug was
originally introduced for the treatment of cancer, particularly
childhood leukaemia, and it was first studied in low dose in
arthritis in the 1960s.  However, concerns surrounded the use
of a chemotherapeutic agent in a chronic disease that at the
time was not considered to have such a bad prognosis.21,22
Renewed interest in the 1980s showed that doses as low as 7.5
mg per week could be beneficial in patients with rheumatoid
arthritis. Several trials confirmed the efficacy and safety of
methotrexate in rheumatoid arthritis in doses ranging from 7.5
to 20 mg per week, and it is now generally considered as the
“gold standard” among the disease modifying drugs.23-25
Until the late 1970s the disease-modifying drugs available
for the treatment of rheumatoid arthritis were considered to be
either too toxic or relatively ineffective.  At the same time, the
prognosis of rheumatoid arthritis was generally considered to
be fairly good, and that although the disease was incurable and
painful, only rarely did it cause serious problems to patients,26
with only 10% being severely disabled 10 years after discharge
from hospital.27  As a result the management of rheumatoid
arthritis developed into a form of a treatment pyramid, starting
with mainly symptomatic measures (such as physical methods
of treatment and the prescription of non-steroidal anti-
inflammatory drugs) with the use of disease-modifying drugs
only being introduced when the disease  progressed further.
Epidemiological studies from rheumatology centres over the
past two decades have not confirmed that rheumatoid arthritis
is such a benign disease.28 Life expectancy is shortened by an
average of about five years,29 and a significant decline in
functional status occurs over time, with about 50% of patients
losing their jobs within 10 years of disease onset.30 Besides,
the long term outcome of traditional treatment of rheumatoid
arthritis using the treatment pyramid, did not prove successful,
with over 50% of patients having died or becoming severely
disabled after 20 years.31
One of the more recent important discoveries in
rheumatoid arthritis was that joint destruction, which is
invariably preceded by synovitis, occurs early in the disease,
and within three years of its onset, over two thirds of patients
show radiographic damage, which is more pronounced during
the first year of disease than during the second or third year.32
These findings, together with the realization that disease-
modifying treatments might be less toxic than was originally
believed, and that the traditional treatment pyramid approach
did not have any noticeable effect on the clinical, radiological
progression and functional aspects and long term prognosis
of the disease, had two important consequences on the
treatment of rheumatoid arthritis.  These were the reappraisal
of treatment strategies, and intense ongoing research to
develop new therapies that can delay or actually prevent joint
destruction.  The emphasis has now shifted to early diagnosis
and treatment with effective disease modifying medication,
either singly or in combination, to suppress inflammation as
quickly and as completely as possible.  Initial therapy may or
may not include glucocorticoids. 33-38
The other important consequence of the current approach
to the treatment of rheumatoid arthritis has been a more
intensive search to develop newer therapies with disease-
modifying properties.  One such medicine has been
leflunomide.  Unlike other medicines, with the possible
exception of sulphasalazine, leflunomide was developed
specifically for use in rheumatoid arthritis as well.  The other
disease-modifying agents used in rheumatoid arthritis had
been in use for other indications before being found to be
effective in rheumatoid arthritis. Leflunomide was discovered
through an in vivo effect in the adjuvant arthritis rat model
when it was shown to reduce the amount of paw oedema and
to diminish the amount of skeletal decay. 39   Studies in humans
showed the drug to be at least as effective as methotrexate;
quality of life studies showed significant improvement with
leflunomide over methotrexate. Compared with sulphasalazine,
leflunomide showed superior physiological function, disease
suppression and patient global assessment. 40-42 Careful
monitoring of the drug is essential because of its potential
heptatotoxicity.  Furthermore, because of its long half life and
teratogenic potential it has to be used very carefully in women
of childbearing age.
The most exciting recent event in the field of rheumatoid
arthritis treatment, however, has been the development of
therapies targeted against specific mediators of the
inflammatory cascade.  At a cellular level, inflammation is a
20 Malta Medical Journal    Volume 16   Issue 02   July 2004
process involving multiple cell types which produce various
inflammatory cytokines that literally make the synovium a
boiling pot of cytokines, chemokines and various other
inflammatory mediators.43  Of these, tumour necrosis factor
alpha (TNF-α) and interleukin-1 (IL-1) have been identified
as the major pro-inflammatory cytokines that, both directly
and indirectly, lead to cartilage and joint damage that are the
hallmark of rheumatoid arthritis.  The isolation of the various
cytokines has led to the development of drugs that target these
cytokines, ushering in the era of biological treatment of
rheumatoid arthritis.  The most effective and widely used are
the TNF-α inhibitors.  This has been the first instance of a
successful “bench to bedside” development which brought a
targeted biological therapy for rheumatoid arthritis into
clinical practice.44 Three TNF-α inhibitors have been licensed
since 1999: etanercept, a chimeric fusion protein where the
tumour necrosis factor receptor is linked to the Fc portion of
human immunoglobulin G, infliximab, a chimeric anti-TNF
monoclonal antibody, consisting of mouse and human
antibody, and adalimumab, a full human anti-TNF
monoclonal antibody.  The use of these drugs is associated
with a high rate of rapid and substantial improvement in signs
and symptoms in patients with rheumatoid arthritis, including
those whose disease has proved resistant to conventional
DMARD therapy. 45-47  The drugs may be used singly or in
combination with methotrexate - combination therapy
possibly being more effective showing sustained remission
and, according to preliminary studies, reversal of joint
damage.48 Long-term safety data with these drugs is not
available, but so far the main risk of side effects associated
with the TNF-α inhibitors is that of infections, including
tuberculosis.    Studies of these agents in early rheumatoid
arthritis are impressive, with a two year study of one of these
agents (infliximab) combined with methotrexate seeming to
inhibit the progression of structural damage and possibly even
leading to healing of erosions: however, these results are still
preliminary.49  Due to the fact that TNF-α inhibitors are very
expensive, as well as the concerns regarding their long-term
safety, they are currently recommended for use in patients
with rheumatoid arthritis who are refractory to other disease
modifying drugs.50
The pace of development of treatments for rheumatoid
arthritis has proceeded at a much more rapid rate over the
past two decades than over the entire previous century.  This
rate of progress was possible because of the increased
understanding of the pathogenesis of the disease leading to
new strategies in controlling it.  As a result, rheumatoid
arthritis treatment has moved from the empirical use of agents
such as gold to specific agents that target pro-inflammatory
cytokines which are known to play a pivotal role in the
pathophysiology of the disease.  However, this is by no means
the end of the story - the development of more potent immune
modulators as well as newer approaches to switch off immune
processes that are responsible for the development of the disease
may result in even more effective therapy, promising an ever
brighter future for patients with rheumatoid arthritis.
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